Altamira Therapeutics Ltd
CYTO
CYTO was delisted on the 19th of December, 2024.
6 hedge funds and large institutions have $34.5K invested in Altamira Therapeutics Ltd in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 7 closing their positions.
54% less funds holding
Funds holding: 13 → 6 (-7)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
71% less capital invested
Capital invested by funds: $119K → $34.5K (-$84.5K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$20K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$36K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$19K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$14.5K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$7K |
| 5 |
HF
HRT Financial
New York
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $18.7K | +$20K | +172 | +860% |
|
2
Morgan Stanley
New York
| $12.1K | -$2.56K | -22 | -15% |
|
|
3
Group One Trading
Chicago,
Illinois
| $3.63K | -$14.5K | -125 | -77% |
|
4
Wells Fargo
San Francisco,
California
| $121 | – | – | – |
|
|
SCA
5
Stonebridge Capital Advisors
St Paul,
Minnesota
| $24 | – | – | – |
|
|
VF
6
Virtu Financial
New York
| – | -$36K | -312 | Closed |
|
|
7
Citadel Advisors
Miami,
Florida
| – | -$19K | -162 | Closed |
|
|
HF
8
HRT Financial
New York
| – | -$6K | -59 | Closed |
|
|
TSS
9
Two Sigma Securities
New York
| – | -$7K | -58 | Closed |
|
10
Renaissance Technologies
New York
| – | -$6K | -50 | Closed |
|
11
Geode Capital Management
Boston,
Massachusetts
| – | -$5K | -47 | Closed |
|
12
Simplex Trading
Chicago,
Illinois
| – | -$2K | -19 | Closed |
|
|
CG
13
Cutler Group
San Francisco,
California
| – | -$813 | -7 | -88% |
|
CYTO Hedge Fund Activity: Q4 2022 in Review
6 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q4 2022, worth a combined $34.5K — down 71% from $119K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CYTO and 0 opened new positions — a net loss of 7 holders — while 3 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $20K. The largest seller was Virtu Financial, exiting entirely with an estimated $36K sold.
- 6 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q4 2022, down from 13 in Q3 2022.
- Funds reported $34.5K of Altamira Therapeutics Ltd stock for Q4 2022, down 71% quarter-over-quarter.
- 0 funds opened new Altamira Therapeutics Ltd positions in Q4 2022 and 7 closed out, a net change of -7 holders.
- The largest Altamira Therapeutics Ltd buyer in Q4 2022 was UBS Group, an estimated $20K added.
- The largest Altamira Therapeutics Ltd seller in Q4 2022 was Virtu Financial, an estimated $36K sold.
Based on aggregated 13F filings for Q4 2022.